Physician profile
Bruce Rashbaum
NPI 1568555456
$85,717.62
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $4,495 · 2021: $62.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $67,043.47 | 2019-2020 | |
| Janssen Products, LP | $15,971.80 | 2019 | |
| Janssen Biotech, INC. | $800.26 | 2019-2021 | |
| Medicure Pharma INC. | $300.00 | 2020 | |
| Theratechnologies INC. | $271.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $188.55 | 2019-2020 | |
| Amgen INC. | $182.02 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $178.36 | 2019-2020 | |
| Novo Nordisk INC | $96.90 | 2019-2020 | |
| Viiv Healthcare Company | $92.82 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.88 | 2019-2020 | |
| Napo Pharmaceuticals INC | $65.62 | 2019 | |
| Endo Pharmaceuticals INC. | $57.31 | 2019-2020 | |
| Mylan Institutional INC. | $55.65 | 2019 | |
| Abbvie INC. | $51.80 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $51.01 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $41.72 | 2019-2020 | |
| Lilly USA, LLC | $33.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.81 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.41 | 2019 | |
| Sanofi Pasteur INC. | $19.30 | 2019 | |
| Pfizer INC. | $16.43 | 2019 | |
| Allergan, INC. | $16.42 | 2020 | |
| Aytu Biopharma, INC. | $15.16 | 2019 | |
| Currax Pharmaceuticals LLC | $13.96 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Rashbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.